United States Pharmacopeia (USP) Quality Standards for Dietary Supplements. Nandu Sarma, PhD, RPh. Director, Dietary Supplements

Size: px
Start display at page:

Download "United States Pharmacopeia (USP) Quality Standards for Dietary Supplements. Nandu Sarma, PhD, RPh. Director, Dietary Supplements"

Transcription

1 United States Pharmacopeia (USP) Quality Standards for Dietary Supplements Nandu Sarma, PhD, RPh. Director, Dietary Supplements ACPM webinar, July 17, 2014

2 Objectives Describe the dietary supplement regulations with regard to quality and safety expectations, Discuss the pharmacopeial perspectives on the quality and safety of dietary supplements, Describe the challenge and tools to address adulteration of dietary supplements. 2

3 Outline U S Pharmacopeia Dietary supplement regulations quality and safety Pharmacopeial perspectives on the quality and safety of dietary supplements, Adulteration of dietary supplements Disclosures I am an employee of US Pharmacopeia I do not have any other financial or professional conflict of interest I do use dietary supplements 3

4 Mission

5 USP Organization What We Do: Establish and disseminate public written standards for the quality, purity, identity, strength, and labeling of medicines, dietary supplements and foods Provide physical Reference Standards to support tests and assays in the USP NF, DSC, HMC and FCC Educate producers, practitioners, and others seeking information on quality and USP standards 5

6 USP: The Organization Who We Are Over 440 volunteer convention members Over 850 volunteer scientists Over 850 paid staff Locations in Rockville, MD, USA Hyderabad, India Basel, Switzerland Shanghai, China São Paulo, Brazil

7 Call for Candidates Web Page

8 USP Resources Official Documentary Standards New Publications with Authorized Information Compendial Reference Materials Verification Services 8

9

10

11 USP's Relationship to FDA USP: Private Not-For-Profit Organization Development and Revision of Compendial Standards Establish Public Standards strength, purity, quality, identity, packaging, labeling FDA: Government Agency Enforcement Safety (GRAS, Food Additive reviews, etc.) 11

12 Outline U S Pharmacopeia Dietary supplement regulations quality and safety Pharmacopeial perspectives on the quality and safety of dietary supplements, Adulteration of dietary supplements 12

13 Dietary Supplement Health & Education Act 1994 Dietary supplements defined Labelling expectations New Dietary Ingredients Good Manufacturing Practices Compliance with USP: optional. A dietary supplement is deemed misbranded if it (i) is covered by the specifications of an official compendium; (ii) is represented as conforming to the specifications of an official compendium; and (iii) fails to so conform. [FDCA 403(s); 21 U.S.C. 343(s)] Dietary Supplement Health and Education Act of 1994, Public Law (Oct. 25, 1994).

14 Dietary Supplement cgmps and USP Manufacturers decide their own specifications for identity, quality, strength, composition and absence of contaminants. Manufacturers decide how to qualify their suppliers in order to avoid 100% testing of components (condition to accept certificate of analysis) Manufacturers decide on the quality of Reference Materials to calibrate analytical equipment USP mentioned many times in the Preamble as a guidance (scientifically valid methods, reference materials, specifications for dietary ingredients, water purity, etc.) Not included as requirement (consistency with DSHEA) FDA's dietary supplement CGMPs: standards without standardization, FDLI, 63 (4), 2008

15 Safety standards for DS under DSHEA SEC 402 [21 USC 342] A food shall be deemed to be adulterated (f) (1) If it is a dietary supplement or contains a dietary ingredient that (A) presents a significant or unreasonable risk of illness or injury under (i) conditions of use recommended or suggested in labeling, or (ii) if no conditions of use are suggested or recommended in the labeling, under ordinary conditions of use; (B) is a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury; (C) the Secretary declares to pose an imminent hazard to public health or safety, except that the authority to make such declaration shall not be delegated and the Secretary shall promptly after such a declaration initiate a proceeding in accordance with sections 554 and 556 of title 5, United States Code, to affirm or withdraw the declaration; or (D) is or contains a dietary ingredient that renders it adulterated under paragraph (a)(1) under the conditions of use recommended or suggested in the labeling of such dietary supplement. In any proceeding under this subparagraph, the United States shall bear the burden of proof on each element to show that a dietary supplement is adulterated. The court shall decide any issue under this paragraph on a de novo basis.

16 Outline U S Pharmacopeia Dietary supplement regulations quality and safety Pharmacopeial perspectives on the quality and safety of dietary supplements, Adulteration of dietary supplements 16

17 White paper 17

18 USP Dietary Supplement Safety Review

19 USP DS Expert Committee: Active Monitoring Program PubMed alert for all the dietary supplements (with monograph in USP) and their marker compounds FDA MedWatch and National Toxicology Program reports British MHRA, Germany, and European Medicines Agency safety alerts TGA (Australia / New Zealand) bulletin Canadian MedEffect bulletin Mailing lists from DS trade associations USP Admission Criteria and Safety Classification for Dietary Supplements Guideline.

20 Evidence-based review Ko et al., Nutrition Reviews, 72(3), , 2014

21 Dietary Supplements Monograph Development 21

22 What is in a USP Monograph? A list of official and validated tests Their analytical procedures Their acceptance criteria In conjunction they define specifications for Identity Quality (Purity, limit for contaminants, Performance and other requirements) Strength Consistent with cgmps for DS

23 Echinacea angustifolia USP 37

24 Echinacea angustifolia USP 37

25 Echinacea angustifolia

26 Echinacea angustifolia

27 Are Disintegration and Dissolution Needed?

28 Goals of Performance Tests Diagnostic Quality Control tool to identify variations in the manufacturing process Confirm the robustness of manufacturing process Predict availability for absorption 28

29 The Value of Public Standards Conservation of FDA and manufacturer resources Uniform standards allow comparisons between products in clinical trials and market place Under DSHEA, consumers don t know to what standards two seemingly equivalent products are held USP promotes Standards with Standardization Private standards not subject to public review - Miller, Celestino, Giancaspro, Williams, Food and Drug Law Journal, 63 (4), 2008

30 Outline U S Pharmacopeia Dietary supplement regulations quality and safety Pharmacopeial perspectives on the quality and safety of dietary supplements, Adulteration of dietary supplements 30

31 Tainted products marketed as Dietary Supplements Phosphodiesterase type 5 inhibitors (e.g., sildenafil) Weightloss drugs (e.g., sibutramine) Controlled substances (e.g., benzodiazepines and anabolic steroids) Anticoagulants (e.g., warfarin) Anticonvulsants (e.g., phenytoin) HMG-CoA reductase inhibitors (e.g., lovastatin) NSAIDs(e.g., indomethacin) Beta blockers (e.g., propranolol) 31

32 General Chapter <2251> Adulteration of Dietary Supplements with Drugs and Drug Analogs Focus on categories of products marketed for sexual enhancement, weight loss, and sport bodybuilding. To develop screening methods for drugs as adulterants for dietary supplements based on the claimed benefits and similar drug effects of such adulterants. 32

33 USP-PDE5i-001-H USP-PDE5i-001-H Bali Mojo CD3CN Extract 1H NMR JCE-PNA-MVX300 2 USP-027-H USP-027-H USP Standard - Tadalafil 1H NMR in CD3CN JCE-PNA-MVX f1 (ppm)

34 Summary USP is a self-supporting, private, non-profit organization. Regulations require use of scientifically valid methods to assure quality of dietary supplements, but may lead to standards without standardization Public standards help conserve resources for the regulators and manufacturers, and help provide confidence for the consumers Uniform standards allow comparisons between products in clinical trials and market place

35 Abbreviations cgmps: current Good Manufacturing Practices ( DS EC: USP Dietary Supplements Expert Committee ( DSC: Dietary Supplements Compendium ( DSHEA: Dietary Supplements Health Education Act ( FCC: Food Chemical Codex ( GRAS: Generally Recognized as Safe ( HMC: Herbal Medicine Compendium ( MHRA: British Medicines and Healthcare Regulation Agency TGA: Australia Therapeutic Goods Administration USP NF: United States Pharmacopeia National Formulary ( 35

36 Nandu Sarma, PhD, RPh. Director, Dietary Supplements Gabriel Giancaspro, PhD. Vice President, Foods Dietary Supplements and Herbal Medicines

The United States Pharmacopeia

The United States Pharmacopeia INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29 February to 2 March 2012 The United States Pharmacopeia Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Roger L.

More information

Catalog. Global Education. and Training. Global Expertise Trusted Standards Improved Health

Catalog. Global Education. and Training. Global Expertise Trusted Standards Improved Health Global Education Catalog 2013 2014 and Training Global Expertise Trusted Standards Improved Health USP s mission is to improve global health through public standards and related programs that help ensure

More information

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs

Introduction to Drug Naming. Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs Introduction to Drug Naming Angela G. Long, M.S. Senior Vice President, Global Alliances and Organizational Affairs What s in a Name? International Nonproprietary Names (INN) Sponsored by World Health

More information

1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY

1083.4 SUPPLY CHAIN INTEGRITY AND SECURITY BRIEFING 1083.4 Supply Chain Integrity and Security. A new series of general informational chapters describing various aspects of the pharmaceutical supply chain replaces Good Distribution Practices Supply

More information

Guidance for Industry Certification Process for Designated Medical Gases

Guidance for Industry Certification Process for Designated Medical Gases Guidance for Industry Certification Process for Designated Medical Gases DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft

More information

A Stability Program for the Distribution of Drug Products

A Stability Program for the Distribution of Drug Products A Stability Program for the Distribution of Drug Products Teresa I. Lucas*, Rafik H. Bishara, and Robert H. Seevers Drug products must be transported in a manner that ensures products will be maintained

More information

USP CONVENTION MEMBERS BY WORLD REGION

USP CONVENTION MEMBERS BY WORLD REGION USP CONVENTION MEMBERS BY WORLD REGION April 1, 2015 The 459 organizations listed below are Voting Organizational Members of the U.S. Pharmacopeial Convention (USP). WORLD (8) International Council of

More information

Veterinary Compounding

Veterinary Compounding Veterinary Compounding Veterinarians occasionally use compounded preparations to meet a specific patient s medical need. The purpose of this brochure, created jointly by the Animal Health Institute (AHI),

More information

Chapter. History and Traditional Technician Roles

Chapter. History and Traditional Technician Roles Chapter 1 History and Traditional Technician Roles 1 9781449629823_CH01_001_014.indd 1 2 History and Traditional Technician Roles Case Study for Discussion Would it be helpful if pharmacists and pharmacy

More information

Stimuli to the Revision Process

Stimuli to the Revision Process 2 STIMULI TO THE REVISION PROCESS of the USPC or the USP Council of Experts Vol. 33(6) [Nov. Dec. 2007] The Application of Uncertainty to USP s Compendial Reference Standards Program: Certified Reference

More information

WHITE PAPER USP S ROLE IN SETTING ENFORCEABLE QUALITY STANDARDS FOR MEDICINES

WHITE PAPER USP S ROLE IN SETTING ENFORCEABLE QUALITY STANDARDS FOR MEDICINES WHITE PAPER USP S ROLE IN SETTING ENFORCEABLE QUALITY STANDARDS FOR MEDICINES SEPTEMBER 23, 2009 COUNCIL OF THE CONVENTION SECTION ON THE QUALITY OF MANUFACTURED MEDICINES INTRODUCTION For nearly two hundred

More information

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance

More information

Third Party Certification Programs for Dietary Supplements

Third Party Certification Programs for Dietary Supplements Third Party Certification Programs for Dietary Supplements A Risk Reduction Step for Athletes. Why third party testing? Independent oversight is important in ensuring quality in any business or industry.

More information

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Implementing New USP Chapters for Analytical Method Validation

Implementing New USP Chapters for Analytical Method Validation Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments

More information

USP Strategic Planning and Initiatives

USP Strategic Planning and Initiatives Prescription/Non-Prescription Stakeholder Forum Meeting #6 for 2010-2015 Tuesday, October 21, 2014 USP Strategic Planning and Initiatives Emily M. Kaine, MD Vice President, Strategy Building from our mission,

More information

Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions

Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions FDLI s Introduction to Medical Device Law and Regulation: Understanding How FDA Regulates the Medical Device Industry October 28-29, 2002 The Westin Grand Hotel Washington, D.C. Premarket Approval Applications

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.

More information

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS. GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au

More information

IN THE UNITED STATES IN 2014,

IN THE UNITED STATES IN 2014, Topics of Professional Interest Quality Certification Programs for Dietary Supplements IN THE UNITED STATES IN 2014, dietary supplements were a $36.7 billion industry. 1 The public has easy access to dietary

More information

Blood, Plasma, and Cellular Blood Components INTRODUCTION

Blood, Plasma, and Cellular Blood Components INTRODUCTION Blood, Plasma, and Cellular Blood Components INTRODUCTION This chapter of the Guideline provides recommendations to Sponsors of Requests for Revision for new monographs for blood, plasma, and cellular

More information

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (11) 204 3R HANDLING AND USE OF REFERENCE STANDARDS IN THE OMCL NETWORK Full document title and reference Document type Legislative

More information

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

USP s mission is to improve global health through public. standards and related programs that help ensure the quality,

USP s mission is to improve global health through public. standards and related programs that help ensure the quality, 2015 Catalog USP s mission is to improve global health through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods. 2 Courses listed as of January

More information

AIS Sports Science/Sports Medicine Best Practice Principles

AIS Sports Science/Sports Medicine Best Practice Principles AIS Sports Science/Sports Medicine Best Practice Principles Introduction For the Australian Sports Commission (ASC) and Australian Institute of Sport (AIS), integrity in sport is paramount. Accordingly,

More information

Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8

Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8 Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v.

More information

Food and Drug Administration, HHS Pt. 212

Food and Drug Administration, HHS Pt. 212 erowe on DSK2VPTVN1PROD with CFR Food and Drug Administration, HHS Pt. 212 investigation was found not to be necessary and the name of the responsible person making such a determination. [43 FR 45077,

More information

General Chapter <800> Open Microphone Web Meeting

General Chapter <800> Open Microphone Web Meeting General Chapter Open Microphone Web Meeting NOTICE TO PARTICIPANTS: To minimize background noise, all lines will be muted upon joining the session. During the meeting, you may ask questions or make

More information

Global Lab Capabilities Pharma Biotech

Global Lab Capabilities Pharma Biotech Global Lab Capabilities Pharma Biotech NSF Health Sciences global network of laboratories delivers expert solutions to pharmaceutical, biotechnology and medical device companies in the areas of analytical

More information

Open Microphone Meeting:

Open Microphone Meeting: Open Microphone Meeting: USP General Chapter Pharmaceutical Compounding Sterile Preparations October 21, 2015 2:00 p.m. to 4:00 p.m. EDT Agenda Welcome Overview of USP s Revision Process Overview

More information

Formulary Management

Formulary Management Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective

More information

Triangle Compounding 11/2/15

Triangle Compounding 11/2/15 Triangle Compounding 11/2/15 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District 60 Eighth Street NE Atlanta, GA 30309 November 2, 2015 VIA UNITED

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

REPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR)

REPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR) REPORT FOR INTERNATIONAL COOPERATION ON COSMETIC REGULATION (ICCR) Principles for the handling of traces of impurities and/or contaminants in cosmetic products Report is: 1 [Choose One] Prepared For ICCR

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Engineering Nanomedical Systems

Engineering Nanomedical Systems BME 695 November 8, 2011 Engineering Nanomedical Systems Lecture 15 GMP and issues of quality control manufacture of nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor

More information

Analysis of Various Vitamins in Multivitamin Tablets

Analysis of Various Vitamins in Multivitamin Tablets High Performance Liquid Chromatography Analysis of Various Vitamins in Multivitamin Tablets Effective August 24, 2007, the US Food and Drug Administration (FDA) issued a regulation (21 CFR Part 111) that

More information

SQF Level 2 Proposed Preventive Controls Comparison Modules 2 & 11

SQF Level 2 Proposed Preventive Controls Comparison Modules 2 & 11 http://leavittpartners.com/global-food-solutions Contact: david.acheson@leavittpartners.com April 2013 SQF Level 2 Proposed Preventive Controls Comparison Modules 2 & 11 Introduction SQF Level 2, which

More information

Minnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015

Minnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015 EXECUTIVE SUMMARY Minnesota Board of Pharmacy Guidance on the Compounding of Veterinary Products Approved: March 4, 2015 Board staff has held several meetings with representatives of the Minnesota Veterinary

More information

The Use of Enzymes in Dietary Supplements USP Enzyme Workshop July 8, 2009

The Use of Enzymes in Dietary Supplements USP Enzyme Workshop July 8, 2009 The Use of Enzymes in Dietary Supplements USP Enzyme Workshop July 8, 2009 Nena Dockery Introduction and History of Use Commercial production of enzymes for use as digestive aids has an extensive history

More information

USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants

USP Pharmaceutical Ingredient Supplier Qualification Program. Manual for Participants USP Pharmaceutical Ingredient Supplier Qualification Program Manual for Participants UNITED STATES PHARMACOPEIA Drug Substance Supplier Qualification Program ICE This manual provides information to drug

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

2014 Annual Report on Inspections of Establishments

2014 Annual Report on Inspections of Establishments 2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered

More information

Importing pharmaceutical products to China

Importing pharmaceutical products to China Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval

More information

Extemporaneously Prepared Early Phase Clinical Trial Materials

Extemporaneously Prepared Early Phase Clinical Trial Materials Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development

More information

IN THE SENATE OF THE UNITED STATES

IN THE SENATE OF THE UNITED STATES II D CONGRESS 1ST SESSION S. 1 To amend title XVIII of the Social Security Act to provide for uniform coverage of anticancer drugs under the medicare program, and for other purposes. IN THE SENATE OF THE

More information

Official Journal of the European Union. (Acts whose publication is obligatory)

Official Journal of the European Union. (Acts whose publication is obligatory) 27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending

More information

2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC

2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC 2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC Objectives 1. Review the changes to the pharmacy practice act related to sterile compounding. 2. Understand the role of the

More information

Proficiency Testing In A Global Analytical Environment Benefits & Challenges. AOAC September 2007

Proficiency Testing In A Global Analytical Environment Benefits & Challenges. AOAC September 2007 Proficiency Testing In A Global Analytical Environment Benefits & Challenges AOAC September 2007 1 The Coca-Cola Company The Coca-Cola Company is the largest manufacturer, distributor and marketer of nonalcoholic

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Commentary USP 36-NF 31. Excerpt Related to General Chapter <17> Prescription Container Labeling

Commentary USP 36-NF 31. Excerpt Related to General Chapter <17> Prescription Container Labeling Commentary USP 36-NF 31 Excerpt Related to General Chapter Prescription Container Labeling In accordance with USP s Rules and Procedures of the Council of Experts ( Rules ), USP publishes all proposed

More information

Pharmacists Pharmacopeia. Official May 1, 2009 August 1, 2009

Pharmacists Pharmacopeia. Official May 1, 2009 August 1, 2009 3 Pharmacists Pharmacopeia Official May 1, 2009 August 1, 2009 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Pharmacists Pharmacopeia of a monograph on any drug

More information

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,

More information

Uniformity of Dosage Units (BP 2011 & USP 34) Ms. Witinee Kongsuk Bureau of Drug and Narcotic Department of Medical Sciences June 14, 2011

Uniformity of Dosage Units (BP 2011 & USP 34) Ms. Witinee Kongsuk Bureau of Drug and Narcotic Department of Medical Sciences June 14, 2011 Uniformity of Dosage Units (BP 2011 & USP 34) Ms. Witinee Kongsuk Bureau of Drug and Narcotic Department of Medical Sciences June 14, 2011 1 Outline : Definition Harmonized general chapter USP 34

More information

Market withdrawal and suspension of marketing authorisation of medicinal product due to good manufacturing practice noncompliance in India

Market withdrawal and suspension of marketing authorisation of medicinal product due to good manufacturing practice noncompliance in India Market withdrawal and suspension of marketing authorisation of medicinal product due to good manufacturing practice noncompliance in India C-269/13 Acino AG vs. European Commission, LS&R 885 Citeersuggestie:

More information

Natural Health Products Bill and Regulations fact versus fiction

Natural Health Products Bill and Regulations fact versus fiction Natural Health Products Bill and Regulations fact versus fiction There is a lot of misunderstanding and misinformation about the Natural Health Products Bill and the associated Regulations. The questions

More information

IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013

IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013 Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is

More information

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.

More information

Pharmacy and Therapeutics Committee Policies and Procedures

Pharmacy and Therapeutics Committee Policies and Procedures Pharmacy and Therapeutics Committee Policies and Procedures I. Charter... p 2 II. Formulary Principles... p 3 III. Drug Review Process... p 4 7 A. When are Medications Reviewed B. How Are Medications Reviewed

More information

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current

More information

Revision of The Dissolution Procedure: Development and Validation 1092

Revision of The Dissolution Procedure: Development and Validation 1092 Page 1 of 5 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Revision of The Dissolution Procedure: Development and Validation

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions

More information

Graduate Education in Pharmacy Schools: Pharmacy Administration

Graduate Education in Pharmacy Schools: Pharmacy Administration Graduate Education in Pharmacy Schools: Pharmacy Administration Developed by: Noel E. Wilkin, R.Ph., Ph.D. Associate Provost Associate Professor, Department Chair: Donna West, RPh, PhD Associate Professor,

More information

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Medical Device Reporting Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Session Overview Purpose: To provide information about the

More information

G. Recalls. http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm.

G. Recalls. http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm. G. Recalls 1. Background When an FDA-regulated product is defective, potentially harmful, or mislabeled, recalling that product removing it from the market or correcting the problem is often the most effective

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug

More information

One Hundred Tenth Congress of the United States of America

One Hundred Tenth Congress of the United States of America S. 1858 One Hundred Tenth Congress of the United States of America AT THE SECOND SESSION Begun and held at the City of Washington on Thursday, the third day of January, two thousand and eight An Act To

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle

FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle Kurt R. Karst Associate Hyman, Phelps & McNamara, P.C. 700 Thirteenth

More information

S. ll IN THE SENATE OF THE UNITED STATES A BILL

S. ll IN THE SENATE OF THE UNITED STATES A BILL TH CONGRESS ST SESSION S. ll To amend the Federal Food, Drug, and Cosmetic Act to require that genetically engineered food and foods that contains genetically engineered ingredients be labeled accordingly.

More information

Finalized by the Codex Alimentarius Commission July 4, 2005 Guidelines for Vitamin and Mineral Food Supplements PREAMBLE

Finalized by the Codex Alimentarius Commission July 4, 2005 Guidelines for Vitamin and Mineral Food Supplements PREAMBLE Revised Version - Text of final Codex Vitamin and Mineral Guideline. Offered for Amendment on behalf of Natural Solutions Foundation and Citizens Working Group on Codex Finalized by the Codex Alimentarius

More information

Natural Health Products Directorate - Direction des produits de santé naturels

Natural Health Products Directorate - Direction des produits de santé naturels Site Licensing & Good Manufacturing Practices Requirements for Natural Health Products in Canada Canadian Association of Professional Regulatory Affairs Annual Education Day - June 5, 2012 Raymond W. Tsang,

More information

Drug Imports Exports Compliance

Drug Imports Exports Compliance Drug Imports Exports Compliance 1 CDER Office of Compliance Office of Drug Security, Integrity & Recalls Division of Import Operations & Recalls Imports Exports Compliance Branch FDA compliance focal point

More information

BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 info@bpsweb.org www.bpsweb.

BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 info@bpsweb.org www.bpsweb. BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 info@bpsweb.org www.bpsweb.org Content Outline for the PEDIATRIC PHARMACY SPECIALTY CERTIFICATION

More information

FOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005)

FOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005) FOOD SAFETY MANAGEMENT SYSTEMS (FSMS): REQUIREMENTS FOR ANY ORGANISATION IN THE FOOD CHAIN (ISO 22000:2005) Dr.R.MANAVALAN, M.Pharm., Ph.D. Professor and Research Director, Department of Pharmaceutics,

More information

FDA Regulation of Health IT

FDA Regulation of Health IT FDA Regulation of Health IT May 2014 Marian J. Lee Partner King & Spalding +1 (202) 661 7955 mlee@kslaw.com Agenda FDA s Mobile Medical Applications Guidance FDASIA Health IT Report 2 FDA s Mobile Medical

More information

TITLE 42 - Section 11601 - Findings and declarations

TITLE 42 - Section 11601 - Findings and declarations TITLE 42 - Section 11601 - Findings and declarations CHAPTER 121 INTERNATIONAL CHILD ABDUCTION REMEDIES Sec. 11601. Findings and declarations. 11602. Definitions. 11603. Judicial remedies. 11604. Provisional

More information

Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates

Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates 14 pharmacists and 1 epidemiologist make up the committee USP staff FDA and CDC representatives have input but do not vote Call for Candidates

More information

Industry Perspective on Managing Risks in a Global Market

Industry Perspective on Managing Risks in a Global Market Industry Perspective on Managing Risks in a Global Market Institute of Medicine Managing Food Safety Practices from Farm to Table September 9, 2008 Robert E. Brackett, Ph.D. Senior Vice President and Chief

More information

Pharmaceutical Quality Systems: US Perspective

Pharmaceutical Quality Systems: US Perspective Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical

More information

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations

More information

Dietary Supplements: What Is Safe?

Dietary Supplements: What Is Safe? Dietary Supplements: What Is Safe? What you need to know first about dietary supplements Dietary supplements include things like vitamins, minerals, herbs, or products made from plants. They can also be

More information

Check List. Telehealth Credentialing and Privileging Sec. 482.12. Conditions of Participation Governing Body

Check List. Telehealth Credentialing and Privileging Sec. 482.12. Conditions of Participation Governing Body Check List Telehealth Credentialing and Privileging Sec. 482.12. Conditions of Participation Governing Body The Centers for Medicare and Medicaid Services (CMS) final rule on credentialing and privileging

More information

Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation

Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Interplay Between FDA Advertising and Promotion Enforcement Activities, Product Liability, and Consumer Fraud Litigation Leslie M. Tector Quarles & Brady LLP September 30, 2014 Objectives Which federal

More information

REGULATIONS FOR THE PHILOSOPHIAE DOCTOR DEGREE (PHD) AT THE NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) 1

REGULATIONS FOR THE PHILOSOPHIAE DOCTOR DEGREE (PHD) AT THE NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) 1 REGULATIONS FOR THE PHILOSOPHIAE DOCTOR DEGREE (PHD) AT THE NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) 1 Passed by the Board of NTNU on 23 January 2012 under the provisions of the Act of 1 April

More information

Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification a

Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification a STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Lifecycle Management of Analytical Procedures: Method Development, Procedure

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

Page 191 TITLE 21 FOOD AND DRUGS 355 1

Page 191 TITLE 21 FOOD AND DRUGS 355 1 Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior

More information

Recent Updates on European Requirements and what QPs are expected to do

Recent Updates on European Requirements and what QPs are expected to do Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status

More information

An Overview of the Regulation of Homeopathic Drug Products in the United States

An Overview of the Regulation of Homeopathic Drug Products in the United States An Overview of the Regulation of Homeopathic Drug Products in the United States and the Role of the Homoeopathic Pharmacopoeia Convention of the United States J.P. Borneman, Ph.D. President, Homoeopathic

More information

A Natural Products Association Presents. SQF Certification. Josh Grauso Technical Sales Director UL Registrar

A Natural Products Association Presents. SQF Certification. Josh Grauso Technical Sales Director UL Registrar A Natural Products Association Presents SQF Certification June 25, 2015 1:00-2:00pm Josh Grauso Technical Sales Director UL Registrar GoToWebinar Housekeeping: Attendee Participation Your Participation

More information

1.0 Introduction Page 2. 2.0 Scope Page 2. 3.0 General Principles of Shelf-life Studies Page 3. 4.0 Selection of Batches Page 4

1.0 Introduction Page 2. 2.0 Scope Page 2. 3.0 General Principles of Shelf-life Studies Page 3. 4.0 Selection of Batches Page 4 Stability Testing Guideline for Dietary Supplements Final Draft January 2011 Provided by the NSF Stability Testing Working Group Table of Contents 1.0 Introduction Page 2 2.0 Scope Page 2 3.0 General Principles

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

Nutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator

Nutraceutical Medical Research, LLC. By: Latesha Richards, Marketing Coordinator The Value of Conducting Post-Marketing Clinical Research On Marketing Strategy Development Nutraceutical Medical Research, LLC By: Latesha Richards, Marketing Coordinator Those of us who are marketing

More information

ISCT Stem Cell Translation: Strategies, Best Practices, and Regulatory Considerations September 28, 2010 USP Standards for Cell and Tissue Therapies

ISCT Stem Cell Translation: Strategies, Best Practices, and Regulatory Considerations September 28, 2010 USP Standards for Cell and Tissue Therapies ISCT Stem Cell Translation: Strategies, Best Practices, and Regulatory Considerations September 28, 2010 USP Standards for Cell and Tissue Therapies Fouad Atouf, Ph.D. Senior Scientific Liaison Biologics

More information

GUIDELINES FOR FOOD IMPORT CONTROL SYSTEMS

GUIDELINES FOR FOOD IMPORT CONTROL SYSTEMS GUIDELINES FOR FOOD IMPORT CONTROL SYSTEMS SECTION 1 SCOPE CAC/GL 47-2003 1. This document provides a framework for the development and operation of an import control system to protect consumers and facilitate

More information

Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions

Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports Martha A. Feldman, RAC Drug & Device Development Co., Inc. Topics for today Post-approval requirements for

More information

PHARMACEUTICAL REFERENCE STANDARDS

PHARMACEUTICAL REFERENCE STANDARDS PHARMACEUTICAL REFERENCE STANDARDS 11 th International Symposium organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe 3-4 September 2012, Strasbourg,

More information